To test the clinical relevance of CD36 enrichment in HER2 + EMT-like stem cells (Fig. 2A), we evaluated the enrichment of the Creighton CD44HighCD24Low MS stemness signature designed specifically to identify EMT-like CSCs [27] in posttherapy HER2 + BC samples vs. their matched baseline counterparts in ΔCD36 + and ΔCD36 − tumors by GSEA (Fig. 2C). This evidence concerns the gene CD36 and breast cancer.